Table 2.
Results of the ANOVAs performed to assess the potential effect of AUT00063 on the RDR, upper limit, and GDT. Data in the second and third columns are adjusted for the effects of sequence and period
| Geometric least-squares adjusted mean | 95 % confidence (2-sided) | Raw geometric mean | p value (2-sided) | |
|---|---|---|---|---|
| RDR | ||||
| AUT00063 | 1.21 | 1.17–1.26 | 1.19 | |
| Placebo | 1.20 | 1.17–1.23 | 1.18 | |
| AUT00063/placebo | 1.01 | 0.96–1.06 | 1.01 | 0.63 |
| Period effect | 0.47 | |||
| Sequence (carry over) effect | 0.26 | |||
| Upper limit | ||||
| AUT00063 | 457 | 349–599 | 447 | |
| Placebo | 491 | 402–600 | 480 | |
| AUT00063/placebo | 0.93 | 0.67–1.30 | 0.93 | 0.65 |
| Period effect | 0.50 | |||
| Sequence (carry over) effect | 0.03 | |||
| GDT | ||||
| AUT00063 | 2.93 | 2.56–3.36 | 2.93 | |
| Placebo | 2.96 | 2.68–3.28 | 2.93 | |
| AUT00063/Placebo | 0.99 | 0.84–1.17 | 1.0 | 0.89 |
| Period effect | 0.20 | |||
| Sequence (carry over) effect | 0.98 | |||